ChemoCentryx
Patents, Design & Utilities
Last updated:
List of all ChemoCentryx patents 128 in total
| Status | Patent |
|---|---|
Application | Utility: AMORPHOUS FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR Filling date: 8 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR Filling date: 8 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES Filling date: 8 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES Filling date: 8 Sep 2025 Issue date: 6 May 2021 |
Grant | Utility: Modulators of chemokine receptors Filling date: 8 Sep 2025 Issue date: 27 Apr 2021 |
Application | Utility: DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS Filling date: 8 Sep 2025 Issue date: 15 Apr 2021 |
Grant | Utility: Method of treating focal segmental glomerulosclerosis Filling date: 8 Sep 2025 Issue date: 13 Apr 2021 |
Application | Utility: 2-OXINDOLE COMPOUNDS Filling date: 8 Sep 2025 Issue date: 8 Apr 2021 |
Application | Utility: DIAZOLE LACTAMS Filling date: 8 Sep 2025 Issue date: 1 Apr 2021 |
Application | Utility: IMMUNOMODULATOR COMPOUNDS Filling date: 8 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS Filling date: 8 Sep 2025 Issue date: 25 Feb 2021 |
Grant | Utility: Immunomodulator compounds Filling date: 8 Sep 2025 Issue date: 16 Feb 2021 |
Grant | Utility: Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation Filling date: 8 Sep 2025 Issue date: 26 Jan 2021 |
Application | Utility: DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS Filling date: 8 Sep 2025 Issue date: 14 Jan 2021 |
Application | Utility: INDANES AS PD-L1 INHIBITORS Filling date: 8 Sep 2025 Issue date: 14 Jan 2021 |
Application | Utility: 5-5 FUSED RINGS AS C5a INHIBITORS Filling date: 8 Sep 2025 Issue date: 14 Jan 2021 |
Application | Utility: TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS Filling date: 8 Sep 2025 Issue date: 7 Jan 2021 |
Application | Utility: COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES Filling date: 8 Sep 2025 Issue date: 7 Jan 2021 |
Application | Utility: TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES Filling date: 8 Sep 2025 Issue date: 10 Dec 2020 |
Application | Utility: INDANE-AMINES AS PD-L1 ANTAGONISTS Filling date: 8 Sep 2025 Issue date: 3 Dec 2020 |
Application | Utility: PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS Filling date: 8 Sep 2025 Issue date: 12 Nov 2020 |
Grant | Utility: Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors Filling date: 8 Sep 2025 Issue date: 10 Nov 2020 |
Application | Utility: 6-5 FUSED RINGS AS C5a INHIBITORS Filling date: 8 Sep 2025 Issue date: 5 Nov 2020 |
Application | Utility: Method of Treating Focal Segmental Glomerulosclerosis Filling date: 8 Sep 2025 Issue date: 15 Oct 2020 |
Grant | Utility: Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies Filling date: 8 Sep 2025 Issue date: 6 Oct 2020 |
Grant | Utility: CCR6 compounds Filling date: 8 Sep 2025 Issue date: 29 Sep 2020 |
Application | Utility: Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor Filling date: 8 Sep 2025 Issue date: 24 Sep 2020 |
Application | Utility: REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS Filling date: 8 Sep 2025 Issue date: 17 Sep 2020 |
Grant | Utility: 2-oxindole compounds Filling date: 8 Sep 2025 Issue date: 1 Sep 2020 |
Grant | Utility: Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors Filling date: 8 Sep 2025 Issue date: 1 Sep 2020 |
Grant | Utility: Treatment of focal segmental glomerulosclerosis with CCR2 antagonists Filling date: 8 Sep 2025 Issue date: 1 Sep 2020 |
Application | Utility: COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES Filling date: 8 Sep 2025 Issue date: 27 Aug 2020 |
Application | Utility: Method of Treating Liver Fibrosis Filling date: 8 Sep 2025 Issue date: 27 Aug 2020 |
Application | Utility: SOLUBLE C5aR ANTAGONISTS Filling date: 8 Sep 2025 Issue date: 20 Aug 2020 |
Grant | Utility: Diazole lactams Filling date: 8 Sep 2025 Issue date: 18 Aug 2020 |
Application | Utility: Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides Filling date: 8 Sep 2025 Issue date: 25 Jun 2020 |
Application | Utility: CXCR7 INHIBITORS FOR THE TREATMENT OF CANCER Filling date: 8 Sep 2025 Issue date: 18 Jun 2020 |
Grant | Utility: 5-5 fused rings as C5a inhibitors Filling date: 8 Sep 2025 Issue date: 16 Jun 2020 |
Grant | Utility: Method of treating liver fibrosis Filling date: 8 Sep 2025 Issue date: 16 Jun 2020 |
Application | Utility: METHODS OF TREATING PANCREATIC CANCER Filling date: 8 Sep 2025 Issue date: 11 Jun 2020 |
Application | Utility: CAPSULE FORMULATIONS Filling date: 8 Sep 2025 Issue date: 4 Jun 2020 |
Grant | Utility: C5aR antagonists Filling date: 8 Sep 2025 Issue date: 26 May 2020 |
Application | Utility: Heteroaryl Sulfonamides and CCR2/CCR9 Filling date: 8 Sep 2025 Issue date: 14 May 2020 |
Grant | Utility: Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists Filling date: 8 Sep 2025 Issue date: 12 May 2020 |
Application | Utility: INHIBITORS OF CXCR2 Filling date: 8 Sep 2025 Issue date: 7 May 2020 |
Grant | Utility: Immunomodulator compounds Filling date: 8 Sep 2025 Issue date: 5 May 2020 |
Application | Utility: SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS Filling date: 8 Sep 2025 Issue date: 23 Apr 2020 |
Application | Utility: SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS Filling date: 8 Sep 2025 Issue date: 23 Apr 2020 |
Application | Utility: 2-OXINDOLE COMPOUNDS Filling date: 8 Sep 2025 Issue date: 23 Apr 2020 |
Application | Utility: COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES Filling date: 8 Sep 2025 Issue date: 16 Apr 2020 |
Showing 50 to 100 of 128 patents.